Efficacy and Safety of Polatuzumab Vedotin in Combination With Zanubrutinib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma of the MCD/BN2/N1 Subtypes

Abroad (travel likely)RecruitingPHASE2

Conditions

Diffuse Large B-Cell Lymphoma (DLBCL)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Jiangsu Province Hospital, Nanjing, Jiangsu, China
Contact: Study coordinator (Jinhua Liang, MD) · 1151525490@qq.com · 15952032421
Contact: Study coordinator (Wei Xu) · xuwei10000@hotmail.com

Study leads

Wei Xu, PHD
Principal Investigator
Hematological Department, Jiangsu Province Hospital

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+

Diffuse Large B-cell Lymphoma · DLBCL - Diffuse Large B Cell Lymphoma

Abroad (travel likely)RecruitingPHASE2

Richmond, United States

Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL

Diffuse Large B-Cell Lymphoma

Abroad (travel likely)RecruitingPHASE2

Berkeley, United States · La Jolla, United States

Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients

Relapsed Large B-cell Lymphoma · Refractory Large B-cell Lymphoma · Diffuse Large B-cell Lymphoma (DLBCL)

Abroad (travel likely)RecruitingPHASE1, PHASE2

Seoul, South Korea

CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL

Diffuse Large B-Cell Lymphoma (DLBCL)

Abroad (travel likely)RecruitingPHASE2

Tianjin, China